Dr. Sharma is the principal investigator of
multiple immunotherapy trials and performs extensive laboratory studies on patients» samples to gain insights regarding mechanisms and pathways involved in antitumor responses.
Not exact matches
Speaking of checkpoint inhibitor drugs... Merck's star cancer
immunotherapy treatment Keytruda is facing some troubling clinical
trial incidents which have now compelled the Food and Drug Administration (FDA) to halt three studies of the drug in
multiple myeloma, a rare blood cancer, after a number of patient deaths.
Wherry, together with his colleagues in the Parker Institute for Cancer
Immunotherapy at Penn, are involved in
multiple checkpoint - related
trials, in melanoma, lung cancer, renal cell carcinoma, and others, including combining checkpoint blockade with radiation.
This page features information on
multiple myeloma and
immunotherapy clinical
trials for
multiple myeloma patients, and highlights the Cancer Research Institute's role in working to bring effective immune - based cancer treatments to people with
multiple myeloma.
There are now
multiple immunotherapies targeting clearance of alpha - synuclein from the brain in early - stage clinical
trials, and
multiple trials underway or in the works on the next generation of cell replacement therapies for dopaminergic neurons, including the TRANSEURO
trial; the Summit4StemCell initiative, put together by Jeanne Loring — a researcher at The Scripps Research Institute who is exceptionally engaged with turning her research into therapies; a Japanese
trial to be run by Jun Takahashi of Kyoto University in Japan (cf. here and here); and a
trial centered at Memorial Sloan Kettering Cancer Center headed by cell biologist Lorenz Studer.
«A
trial of this magnitude has many moving parts:
multiple contracts and co-funders, a four - drug IND, a major industry partner, a biotech firm, and six university hospitals,» said Ramy Ibrahim, M.D., vice president of clinical development at the Parker Institute for Cancer
Immunotherapy.
In addition, a growing number of
immunotherapy clinical
trials are in place to test this groundbreaking approach on other cancers like lymphoma,
multiple myeloma, and for solid tumors, through
trials in glioblastoma, mesothelioma, and ovarian and pancreatic cancer.